Top Markets
Coin of the day
Perseus Proteomics Inc. Perseus Proteomics Inc.

Perseus Proteomics Inc.

4882
Rank in Stocks #30348
Based in Tokyo, Japan, Perseus Proteomics Inc. operates as a biotechnology... Based in Tokyo, Japan, Perseus Proteomics Inc. operates as a biotechnology venture specializing in the development of antibody-based therapeutics for various ailments, including cancer. Its core operations encompass pioneering antibody discovery, alongside providing extensive research support services. These services include hybridoma antibody sequencing, the production of antibody proteins, and undertaking contract antibody research projects. Furthermore, Perseus Proteomics supplies its own antibody products to the market. The company boasts a robust development pipeline featuring several promising candidates: PPMX-T001, an antibody targeting hepatocarcinoma; PPMX-T002, an oncology therapeutic; PPMX-T003, designed for the treatment of adult T-cell leukemia/lymphoma; and PPMX-T004, an innovative antibody-drug conjugate. Established in 2001, the firm maintains its headquarters in the Japanese capital.
Share Price
$0.93298493
Market Cap
$17.19M
Change (1 day)
-1.38%
Change (1 year)
-62.47%
Country
JP
Trade Perseus Proteomics Inc. (4882)

Category

P/B ratio for Perseus Proteomics Inc. (4882)
P/B ratio as of 2026 TTM: 0
According to Perseus Proteomics Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Perseus Proteomics Inc. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
31.0864 -
US
7.4766 -
US
-74.4354 -
US
8.4776 -
CH
8.008 -
US